Rep. Julie Johnson Sells Off Shares of AbbVie Inc. (NYSE:ABBV)

Representative Julie Johnson (D-Texas) recently sold shares of AbbVie Inc. (NYSE:ABBV). In a filing disclosed on December 11th, the Representative disclosed that they had sold between $1,001 and $15,000 in AbbVie stock on November 13th. The trade occurred in the Representative’s “CHASE BROKERAGE ACCOUNT (3935)” account.

Representative Julie Johnson also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Charles Schwab (NYSE:SCHW) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Cigna Group (NYSE:CI) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Xcel Energy (NASDAQ:XEL) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Capital One Financial (NYSE:COF) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Walmart (NASDAQ:WMT) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Wells Fargo & Company (NYSE:WFC) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 11/13/2025.

AbbVie Stock Performance

Shares of AbbVie stock opened at $223.45 on Monday. The company has a 50 day moving average price of $227.25 and a 200 day moving average price of $209.95. The firm has a market capitalization of $394.92 billion, a P/E ratio of 169.28, a PEG ratio of 1.21 and a beta of 0.36. The company has a quick ratio of 0.60, a current ratio of 0.72 and a debt-to-equity ratio of 44.14. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. During the same quarter in the prior year, the business posted $3.00 EPS. AbbVie’s revenue for the quarter was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Sell-side analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio is currently 496.97%.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Citigroup reduced their target price on AbbVie from $240.00 to $235.00 and set a “neutral” rating for the company in a research note on Monday, November 3rd. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, October 8th. Hsbc Global Res upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, December 10th. Berenberg Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating and increased their price target for the stock from $170.00 to $270.00 in a report on Wednesday, September 17th. Finally, BMO Capital Markets lifted their price objective on shares of AbbVie from $215.00 to $240.00 and gave the company an “outperform” rating in a research note on Friday, September 12th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $244.55.

Institutional Investors Weigh In On AbbVie

Hedge funds have recently bought and sold shares of the stock. Chelsea Counsel Co. purchased a new stake in AbbVie during the third quarter worth $26,000. TD Capital Management LLC increased its holdings in AbbVie by 82.9% in the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after buying an additional 58 shares in the last quarter. Marshall & Sullivan Inc. WA purchased a new stake in shares of AbbVie during the 2nd quarter worth about $25,000. Texas Capital Bancshares Inc TX purchased a new stake in shares of AbbVie during the 3rd quarter worth about $31,000. Finally, Evolution Wealth Management Inc. acquired a new stake in shares of AbbVie during the 2nd quarter valued at about $26,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.